Context Therapeutics (CNTX) UBS Global Healthcare Conference summary

Pipeline and clinical development

• Expanded from one to three T-cell engager assets in 2023, targeting Claudin 6, mesothelin, and Nectin-4.

• Claudin 6 program is in phase I, focusing on ovarian and endometrial cancers, with initial data expected in H1 2026.

• Mesothelin program to enter clinic in early 2025, targeting ovarian, pancreatic, and mesothelioma, with initial data also expected in H1 2026.

• Nectin-4 asset acquired from BioAtla, with IND filing planned and clinical entry projected within 18 months.

• All programs are designed for potential combination with ADCs or other agents to maximize efficacy.

Competitive differentiation and scientific rationale

• Focuses on targets validated by ADCs, leveraging combination potential and different mechanisms of action.

• Uses high-affinity CD3 for greater potency, while competitors often use weaker payloads due to safety concerns.

• Employs step dosing and prednisone to manage cytokine release syndrome, enabling higher efficacy dosing.

• Claudin 6 is highly tumor-restricted, with antibody selectivity achieved after extensive development.

• Nectin-4 program uses avidity enhancement and pH-dependent binding to improve tumor selectivity and reduce off-tumor effects.

Study design and timelines

• Claudin 6 phase I/II uses step dosing, single-patient cohorts, and rapid escalation, with Project Optimus guiding dose selection.

• Mesothelin phase I will use a Bayesian adaptive design, starting with ovarian and expanding to other tumor types.

• Nectin-4 trial will focus on resistance and combination strategies, with a large eligible patient population.

• Initial data for Claudin 6 and mesothelin expected in H1 2026; Nectin-4 clinical entry in 12–18 months.